Skip To Main Content
Daniel A. Pollyea on Muck Rack

Daniel A. Pollyea

Denver
As seen in: Nature, Wiley Online Library, Cell Stem Cell, EClinicalMedicine, The Lancet, Healio, Cancer Discovery, Texas Medical Center, Blood, OncLive and
The Leukemologist
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Daniel A.

Contact Daniel A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies

|
By Keith W Pratz, Courtney DiNardo, Martha Arellano, Michael J. Thirman, Vinod Pullarkat, Pamela S Becker, B. Douglas Smith, Meng Zhang, Jalaja Potluri, Daniel A. Pollyea, Kaylee Miu
| Wiley Online Library Verified
To the Editor, Allogeneic hematopoietic stem cell transplantation (SCT) remains the most effective curative treatment for patients with intermediate- and poor-risk acute myeloid leukemia (AML). Patients ineligible for intensive chemotherapy due to age or comorbidities have historically not been candidates for SCT.
Open in Who Shared Issue with article?

Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial

|
By Daniel A. Pollyea, Brett Stevens, Diana Abbott, Maria Amaya
| EClinicalMedicine Verified
Keywords Myelodysplastic syndromes Clinical trial Phase 1/2 Omacetaxine Azacitidine Evidence before this study This clinical trial is the first to combine the protein synthesis inhibitor omacetaxine mepesuccinate with azacitidine for previously untreated patients with myelodysplastic syndromes (MDS) with excess blasts (EB).
Open in Who Shared Issue with article?

"Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with " by Daniel A Pollyea, Courtney D DiNardo et al.

|
By Daniel A. Pollyea
| Texas Medical Center
Abstract Purpose: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML). Patients and methods: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine or placebo + azacitidine and a prior phase Ib study (NCT02203773) where patients were treated with venetoclax + azacitidine.
Open in Who Shared Issue with article?
See all 52 licensed articles (63 Total)